Alto Neuroscience, Inc. (ANRO)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-01

Key Insights

Alto Neuroscience reported positive topline data from a Phase 2 proof-of-concept study for its lead drug candidate ALTO-101, suggesting potential therapeutic benefits for patients.
The company highlighted advancements in its pipeline, indicating a robust research and development program focused on developing novel therapies for central nervous system disorders.
As an emerging growth company, Alto Neuroscience may benefit from the extended transition period for complying with new or revised financial accounting standards, providing flexibility in its reporting requirements.

Current Report Filed: 2026-03-16

Key Insights

Alto Neuroscience reported its fiscal year 2025 financial results, highlighting the company's continued growth and development of its pipeline of central nervous system therapies.
The company's cash and cash equivalents position of $150 million suggests it has sufficient funding to advance its clinical programs in the near term.
Investors will be looking for updates on the progress of Alto's lead product candidates, including the timelines for key milestones such as clinical trial readouts and regulatory submissions.

Annual Report Filed: 2026-03-16

Key Insights

The company reported a net loss of $44.962 million for the fiscal year 2025, indicating continued significant investment in research and development for its clinical-stage assets.
Alto Neuroscience raised $379 million in gross proceeds from an IPO in 2024, providing a strong cash position to advance its pipeline.
The company has secured various debt financing agreements, including a loan and security agreement and an amended loan agreement, to support its operations and development activities.

Current Report Filed: 2026-03-16

Key Insights

Alto Neuroscience, Inc. has raised approximately $120 million in a private placement of common stock and pre-funded warrants, which will provide additional funding to support the company's operations and development efforts.
The company has agreed to file a registration statement with the SEC within 30 days to register the resale of the shares issued in the private placement, providing liquidity for the investors.
The company has expanded its Board of Directors to seven members, likely to provide additional oversight and guidance as it continues to grow.

Insider Trading Filed: 2026-01-06

Key Insights

Ramiro Sanchez, a director of Alto Neuroscience, Inc. (ANRO), acquired 3,806 stock options on January 2, 2026 with an exercise price of $16.59 per share.
The options will vest over the course of 2026, with 952 shares vesting on March 31, 951 on June 30, 952 on September 30, and 951 on December 31, subject to Sanchez's continued service.
The options were granted to Sanchez in lieu of $45,000 in director retainer fees, suggesting the company is compensating board members through equity incentives.

Insider Trading Filed: 2026-01-06

Key Insights

The reporting person Manji Husseini, who is a director of Alto Neuroscience, Inc. (ANRO), acquired 4,228 stock options at an exercise price of $16.59 on January 2, 2026. This could signal the director's confidence in the company's future performance.
The options granted to the director will vest over the course of 2026, with 1,057 shares vesting each quarter, indicating a long-term commitment to the company.
The options were granted as part of the company's Non-Employee Director Compensation Policy, suggesting a structured approach to incentivizing and retaining board members.

Insider Trading Filed: 2026-01-06

Key Insights

The reporting person, Christopher Nixon Cox, has been granted a stock option to purchase 7,189 shares of the issuer's common stock at an exercise price of $16.59 per share. The option will vest in four equal installments over the next year, subject to the reporting person's continued service.
The option grant appears to be part of the issuer's non-employee director compensation policy, as the exercise price is discounted to the fair market value of the stock on the grant date.
The reporting person's ownership of the issuer's securities remains at a direct ownership level, indicating no significant changes to his beneficial ownership position.

Insider Trading Filed: 2026-01-06

Key Insights

The reporting person, Gwill York, was granted a stock option to purchase 5,243 shares of the issuer's common stock, with the shares vesting quarterly over 2026.
The option was issued to York in lieu of $62,000 in retainer fees, suggesting the company is compensating directors with equity to conserve cash.
This direct ownership of company shares by a director indicates their alignment with shareholder interests and confidence in the company's long-term prospects.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.